ELEVAI Labs established two subsidiaries: ELEVAI Biosciences, Inc., and ELEVAI Skincare, Inc. ELEVAI Biosciences will focus on acquiring and developing…
Read More »Biotech
The agreement adds two drug candidates to the company’s product pipeline, “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”,…
Read More »
The company’s international distribution agreements have a contracted cumulative minimum purchase requirement of up to $4.9 million over the first…
Read More »
The Asia-Pacific market represents a $13 billion prestige skincare and luxury haircare market opportunity, with the Taiwan deal giving the…
Read More »
With the obesity drug market poised for exponential future growth, here’s the skinny on the top obesity and weight-loss stocks…
Read More »
The company also reported record Q4 2023 revenue of $698,591, up 403% over the previous quarter. Elevai Labs Inc. (NASDAQ:…
Read More »
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of…
Read More »
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an…
Read More »
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announced today the signing of a licensing agreement…
Read More »
Elevai Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today announced the closing of its previously announced…
Read More »